BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26339916)

  • 1. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
    Vízkeleti L
    Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CCND1 alterations during the progression of cutaneous malignant melanoma.
    Vízkeleti L; Ecsedi S; Rákosy Z; Orosz A; Lázár V; Emri G; Koroknai V; Kiss T; Ádány R; Balázs M
    Tumour Biol; 2012 Dec; 33(6):2189-99. PubMed ID: 23001925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.
    Lázár V; Ecsedi S; Szöllosi AG; Tóth R; Vízkeleti L; Rákosy Z; Bégány A; Adány R; Balázs M
    Mod Pathol; 2009 Oct; 22(10):1367-78. PubMed ID: 19633643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of the expressions of CAV1 and TES genes on 7q31 in melanoma.
    Vizkeleti L; Ecsedi S; Rakosy Z; Begany A; Emri G; Toth R; Orosz A; Szollosi AG; Mehes G; Adany R; Balazs M
    Front Biosci (Elite Ed); 2012 Jan; 4(5):1802-12. PubMed ID: 22201996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
    Puig-Butillé JA; Badenas C; Ogbah Z; Carrera C; Aguilera P; Malvehy J; Puig S
    Exp Dermatol; 2013 Feb; 22(2):148-50. PubMed ID: 23362874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
    Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
    Wroblewska JP; Mull J; Wu CL; Fujimoto M; Ogawa T; Marszalek A; Hoang MP
    Am J Surg Pathol; 2019 Feb; 43(2):168-177. PubMed ID: 30273197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.